好药价

最新新闻

• 评级变动
  TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $5
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• GoodRx(GDRX.US) 10% Shareholder Sells US$4.2 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/22
• 评级变动
  Raymond James Maintains GoodRx(GDRX.US) With Buy Rating, Announces Target Price $4.5
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $3.5
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• 评级变动
  A Quick Look at Today's Ratings for GoodRx(GDRX.US), With a Forecast Between $4 to $5
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Raises Target Price to $5
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• GoodRx(GDRX.US) 10% Shareholder Sells US$5.48 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  Citi Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $4
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), MBX Biosciences, Inc. (MBX) and GoodRx Holdings (GDRX)
  TipRanks · 2026/6/10
• 评级变动
  Goldman Sachs Maintains GoodRx(GDRX.US) With Hold Rating, Raises Target Price to $4
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $4
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• UBS Maintains GoodRx(GDRX.US) With Hold Rating, Raises Target Price to $3.75
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Morgan Stanley Maintains GoodRx(GDRX.US) With Hold Rating, Raises Target Price to $4
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Raises Target Price to $2.65
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $2.65
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  Citi Maintains GoodRx(GDRX.US) With Buy Rating, Raises Target Price to $4
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• 评级变动
  Citi Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $5
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: GoodRx Holdings (GDRX), Xencor (XNCR) and PepGen Inc. (PEPG)
  TipRanks · 2026/8/6
• 评级变动
  Citi Maintains GoodRx(GDRX.US) With Buy Rating, Raises Target Price to $5
  \u5e02\u573a\u8d44\u8baf · 2026/8/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。